Clinical-stage biotech developing antibody and siRNA therapeutics for infectious disease, with a growing oncology pipeline built on its PRO-XTEN masking platform.
The Gilead Sciences deal, which includes $135 million in upfront and near-term payments, marks a critical platform validation for Vir Biotechnology as investors await an upcoming readout in solid tumors.
Looking to expand its oncology portfolio, Gilead Sciences has tapped Vir Biotechnology's masked T-cell engager (TCE) tech in a potential $1.9 billion biobucks deal. | Looking to expand its oncology portfolio, Gilead has tapped Vir Biotechnology's masked T-cell engager tech in a potential $1.9 billion biobucks deal.
Vir looks to Liu to lead late-stage push—Chutes & Ladders
President, Chief Executive Officer and Director (CEO since April 2023)
Executive Vice President and Chief Business Officer